AngioDynamics (ANGO) Q4 FY26 earnings call

Earnings call· May 2026 (Q4 FY26)· Health Care· Jul 14, 2026

Source: earnings call transcript

AngioDynamics capped off FY26 with strong MedTech growth, particularly in NanoKnife and Auryon, driving improved gross margins and positive cash flow despite tariff headwinds. The company is strategically investing in clinical data and commercial execution to sustain above-market growth in its MedTech platforms, while managing profitability and maintaining a debt-free balance sheet for FY27.

You’re reading a preview. Opening the full call uses 1 concall credit.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.